Last reviewed · How we verify
Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction
Study of the what the body does to the drug in subjects with mild, moderate, and sever liver dysfunction (not working properly)
Details
| Lead sponsor | Sumitomo Pharma America, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 44 |
| Start date | 2016-05 |
| Completion | 2016-11 |
Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Binge-Eating Disorder Disorder
Interventions
- dasotraline
Primary outcomes
- Plasma PK parameters: Area under the plasma/serum concentration-time curve from time zero to infinity (AUC0 inf) — Day 1 -28
Plasma PK parameters: Area under the plasma/serum concentration-time curve from time zero to infinity (AUC0 inf) - Plasma PK parameters: time of occurrence of Cmax — Day 1 -28
Plasma PK parameters: time of occurrence of Cmax
Countries
United States